|
|
 |
|
Viewing report
|
|
|
|
Post-Genomic Biomarkers: Revolutionizing Drug Development and Diagnostics 2nd Edition
Drug and Market Development Publishing, March 2005, Pages: 211
Post-genomic biomarker-based diagnostic products are projected to grow from $100 million in 2003 to $2 billion by 2008.
Since the publication of the first edition, pharmaceutical and biotechnology companies have broadened from a primary focus on biomarker discovery to greater emphasis on assay development and implementation of biomarker applications. Drug developers have also demonstrated increased interest in imaging-based based biomarkers. The second edition, Post-Genomic Biomarkers: From Discovery to Implementation covers these and other new developments.
About the Author
With more than 20 years technical and market consulting experience, Ken Rubenstein, principal of the Lion Consulting Group, is the author of more than 30 published market and industry research reports, and has consulted for more than 50 biotechnology companies and venture capital firms in areas ranging from opportunities assessment to product development. Dr. Rubenstein played key research and development roles for the Syva Company up to the vice president level. During 12 years with Syva, he co-invented their highly successful EMIT immunoassay technology, developed numerous products, and directed both project management and strategic planning activities. Dr. Rubenstein received his doctorate in chemistry from the University of Wisconsin, and did two years post-doctoral training in microbiology and molecular biology at the University Of Pennsylvania School Of Medicine.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Biomarker Technology Platforms for Cancer Diagnoses and Therapies
Biomarkers 2008
European Biomarker Analysis Market
It's All About the Biomarkers: How 2008's Biomarker-Based Partnering Is Driving Personalized Medicine
Clinical Proteomics: Rethinking Approaches to Protein Biomarker Discovery
Cancer, CNS & Cardiovascular Biomarkers: Players, Products and Prospects
Biomarkers - Advanced Technologies and Global Market (2009-2014)
Advances in Biomarkers
Licensing Strategies for Accessing Biomarker Technologies
Biomarker and Diagnostic Opportunities Associated with Targeted Cancer Therapies
How Overcoming the Challenge of Biomarker Validation Can Pay Off for Drug and Diagnostic Developers
Biomarker and Diagnostic Opportunities in Clinical Research for Neurological Diseases
|
|
|
|
